Getting Ahead of Migraine: Integrating Preventive Strategies Into Migraine Care – Live Stream

Live Stream – Getting Ahead of Migraine: Integrating Preventive Strategies Into Migraine Care

CMEO Webcast

Live Webcast: Wednesday, April 18, 2018
7:30 PM – 9:00 PM ET
6:30 PM – 8:00 PM CT

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (ABIM)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, April 18, 2019

Faculty

Andrew C. Charles, MD Andrew C. Charles, MD
Professor of Neurology
Meyer and Renee Luskin Chair in Migraine and Headache Studies
Director, Goldberg Migraine Program
David Geffen School of Medicine, University of California, Los Angeles
Los Angeles, CA
Grace Forde, MD Grace Forde, MD
Director of Neurological Services
North American Partners in Pain Management, LLP
Lake Success, NY

Statement of Need

Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients.

In this interactive session, faculty will discuss the evidence for these new agents, share strategies to address migraine prophylaxis, and translate evidence to real-world clinical practice utilizing case based learning and interactive iPad technologies to engage learners and optimize changes in practice for healthcare providers.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply knowledge of clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
  • Assess safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
  • Employ a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Identify clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
  • Explain safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
  • Describe a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

Financial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

This activity is supported by an educational grant from Teva Pharmaceuticals.

Target Audience

Physicians, physician assistants, nurse practitioners, and pharmacists who treat patients with migraine.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Credit (American Association of Nurse Practitioners):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.0 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-009-L01-P
Enduring: 0376-0000-18-009-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST26359 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Andrew Charles disclosed he serves as consultant for Alder BioPharmaceuticals Inc.; Amgen Inc.; Biohaven Pharmaceuticals; Eli Lilly and Company and eNeura, Inc.

Dr. Grace Forde disclosed she is on the Speakers Bureau for Allergan and Supernus Pharmaceuticals, Inc.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff(planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.